Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1131-1133

  Herold, Tina Rike ^a   Jakl, Veronika ^a   Graser, Anno ^a   Eibl Lindner, Kirsten ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hemianopia; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN; MEFLOQUINE; MIRTAZAPINE; NATALIZUMAB;

ADULT; ARTICLE; CASE REPORT; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; EYE EXAMINATION; FEMALE; HEMIANOPIA; HUMAN; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; LIMB WEAKNESS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT DURATION; VIRUS DETECTION; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 84930476267     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S30636     Document Type: Article

References (10)

1. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multifocal sclerosis with natalizumab-associated progressive leukencephalopathy. Acta Neuropathol. 2012;123:235-245.
2. Downes S, Black GC, Hyman N, Simmonds M, Morris J, Barton C. Visual loss due to progressive multifocal leukoencephalopathy in a congenital immunodeficiency disorder. Arch Opthalmol. 2001;119:1376-1378.
3. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438-446.
4. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011;17:708-719.
5. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10:745-758.
6. Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol. 2010;67:1391-1394.
7. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76:1697-1704.
8. Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and how can it be avoided? Arch Neurol. 2010;67:923-930.
9. ÓConnor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858-1865.
10. Schaaf SM, Pitt D, Racke MK. What happens when natalizumab therapy is stopped? Expert Rev Neurother. 2011;11:1247-1250.